Luminal toxins and small molecules in the gastrointestinal tract

Luminal toxins and small molecules in the gastrointestinal tract represent a diverse group of substances targeted by non-systemic therapeutic agents to prevent systemic absorption or local damage. This category includes exogenous toxins from ingestion, endogenous metabolites like bile acids and phosphate, and pathogenic proteins such as Clostridioides difficile toxins [1, 2, 4]. Unlike traditional drug targets that involve cellular receptors or enzymes, these entities are addressed within the gut lumen through physical or chemical sequestration [3, 5]. Pharmacological intervention typically utilizes large, non-absorbable polymers or inorganic salts that bind these molecules through adsorption, chelation, or ion exchange [1, 2, 3]. For example, sevelamer is used to manage hyperphosphatemia in chronic kidney disease by binding dietary phosphate, while activated charcoal serves as a universal adsorbent in acute poisoning [1, 2]. These therapies are generally characterized by a lack of systemic bioavailability, which minimizes systemic side effects but necessitates careful management of potential drug-drug interactions and nutrient malabsorption [3, 5]. This target class is essential for treating conditions where the primary pathology is driven by the presence or accumulation of specific substances within the digestive tract.

Other names

Intestinal luminal contentsEnteric toxinsGastrointestinal small moleculesGut-restricted targetsLuminal noxious agents

Drugs targeting these entities function through physical adsorption, chemical chelation, ion exchange, or direct immunological neutralization within the gastrointestinal lumen to prevent systemic absorption or local pathological effects [1, 2, 3, 4, 5].